Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161996 | 0.92 | NAMPT (0.52) | NAMPTROCK2ROCK1KDRNPC1 | |
| SCHEMBL163880 | 0.89 | NAMPT (0.44) | NAMPTROCK2 | |
| SCHEMBL162199 | 0.83 | ALDH1A1 (0.42) | NAMPTROCK2MAPTMEN1TP53 | |
| SCHEMBL174042 | 0.83 | CNR1 (0.43) | NPC1RAB9AGHSRMEN1KMT2A | |
| SCHEMBL160829 | 0.83 | DGAT1 (0.57) | KDRNPC1RAB9AMAPTKIT | |
| SCHEMBL160057 | 0.83 | DGAT1 (0.54) | KDRNPC1RAB9AMAPTHTT | |
| SCHEMBL162514 | 0.82 | DGAT1 (0.48) | KDRSMN1; SMN2PTPN1 | |
| SCHEMBL162024 | 0.82 | MAPT (0.46) | NPC1RAB9AMAPTMEN1TP53 | |
| SCHEMBL161878 | 0.81 | DGAT1 (0.52) | KDRMAPTKITTP53 | |
| SCHEMBL163078 | 0.81 | DGAT1 (0.46) | NAMPTROCK1KITMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | NAMPT 32/4885ROCK2 2698/4885ROCK1 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.